Equities Analysts Set Expectations for CAPR FY2025 Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Capricor Therapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biotechnology company will post earnings of ($1.39) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $30.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

CAPR has been the subject of a number of other reports. Maxim Group lifted their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. HC Wainwright reiterated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, January 2nd. Finally, Piper Sandler initiated coverage on Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price for the company. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Trading Up 6.0 %

Shares of NASDAQ:CAPR opened at $14.90 on Wednesday. The firm has a market cap of $677.50 million, a PE ratio of -14.06 and a beta of 4.08. The company has a fifty day simple moving average of $15.22 and a 200 day simple moving average of $11.75. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CAPR. SG Americas Securities LLC acquired a new stake in Capricor Therapeutics during the 3rd quarter worth about $133,000. Rhumbline Advisers acquired a new stake in shares of Capricor Therapeutics during the second quarter worth approximately $147,000. The Manufacturers Life Insurance Company purchased a new position in Capricor Therapeutics during the third quarter valued at approximately $161,000. Sassicaia Capital Advisers LLC acquired a new position in Capricor Therapeutics in the 3rd quarter valued at approximately $192,000. Finally, BNP Paribas Financial Markets lifted its position in Capricor Therapeutics by 868.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after buying an additional 15,872 shares in the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.